# Pharmacological Reversal of Neuromuscular Blockade in Critically Ill Patients

> **NCT05993390** · NA · RECRUITING · sponsor: **Seoul National University Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Neuromuscular Blockade
- Critical Illness
- Neurologic Findings

## Interventions

- **DRUG:** Sugammadex
- **DRUG:** Neostigmine

## Key facts

- **NCT ID:** NCT05993390
- **Lead sponsor:** Seoul National University Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-11
- **Primary completion:** 2025-08-14
- **Final completion:** 2025-08-30
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05993390

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05993390, "Pharmacological Reversal of Neuromuscular Blockade in Critically Ill Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05993390. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*